ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment

May 29, 2020

Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with

Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.

 

See more ASCRS coverage here